Pictet Asset Management
BBIO icon

Pictet Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Pictet Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107M Buy
1,448,126
+66,942
+5% +$4.69M 0.1% 212
2026
Q1 		$101M Buy
1,381,184
+110,894
+9% +$8.04M 0.11% 209
2025
Q4 		$97M Buy
1,270,290
+136,939
+12% +$8.99M 0.09% 229
2025
Q3 		$58.9M Sell
1,133,351
-674,083
-37% -$32.9M 0.06% 291
2025
Q2 		$78.5M Sell
1,807,434
-282,834
-14% -$10.3M 0.08% 237
2025
Q1 		$72.4M Buy
2,090,268
+282,796
+16% +$9.54M 0.08% 245
2024
Q4 		$49.6M Sell
1,807,472
-995,585
-36% -$25.7M 0.05% 299
2024
Q3 		$71.1M Buy
2,803,057
+154,100
+6% +$4.05M 0.08% 246
2024
Q2 		$67.1M Sell
2,648,957
-283,472
-10% -$7.75M 0.08% 237
2024
Q1 		$90.6M Buy
2,932,429
+165,244
+6% +$5.62M 0.1% 222
2023
Q4 		$112M Buy
2,767,185
+27,163
+1% +$816K 0.12% 192
2023
Q3 		$72.3M Buy
+2,740,022
New +$77.8M 0.09% 230

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Pictet Asset Management's BBIO Position: Q2 2026 in Review

Pictet Asset Management increased its BridgeBio Pharma (BBIO) stake by 4.8% in Q2 2026, buying an estimated $4.69M and bringing the position to 1,448,126 shares worth $107M. The position accounts for 0.1% of the portfolio, ranked #212.

Pictet Asset Management first reported a position in BBIO in Q3 2023 and has held it in 12 quarters since. The position peaked at $112M in Q4 2023. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Pictet Asset Management held 1,448,126 shares of BridgeBio Pharma worth $107M as of Q2 2026.
  • Pictet Asset Management bought 66,942 BridgeBio Pharma shares in Q2 2026, an estimated $4.69M.
  • BridgeBio Pharma made up 0.1% of Pictet Asset Management's portfolio in Q2 2026, its #212 holding.
  • Pictet Asset Management first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's BridgeBio Pharma position peaked at $112M in Q4 2023.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.